Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 6/20 | 0.62 |
| ▸ | CTSK | P43235 | 5/20 | 0.62 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.60 |
| ▸ | CTSB | P07858 | 2/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.57 |
| ▸ | PPARA | Q07869 | 2/20 | 0.56 |
| ▸ | ACE | P12821 | 1/20 | 0.55 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.54 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3439255 | 1.00 | CTSS (0.62) | CTSSCTSKCACNA1BCTSBCTSL | |
| SCHEMBL85543 | 0.93 | CTSS (0.64) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL22404737 | 0.93 | CTSS (0.64) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL3355326 | 0.93 | CTSS (0.64) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL5887595 | 0.91 | P2RX7 (0.59) | CTSSCTSKCTSBCTSLP2RX7 | |
| SCHEMBL5887598 | 0.91 | P2RX7 (0.59) | CTSSCTSKCTSBCTSLP2RX7 | |
| SCHEMBL7409389 | 0.91 | CTSS (0.65) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL1486267 | 0.91 | CTSS (0.63) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL7235877 | 0.91 | CTSS (0.63) | CTSSCTSKCTSBCTSLPPARA | |
| SCHEMBL7409385 | 0.91 | CTSS (0.65) | CTSSCTSKCTSBCTSLPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | UNIV NEW YORK STATE RES FOUND (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4496837-A2 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | The Research Foundation for The State University of New York (US) | 2025-01-29 | — | — | EP | disclosed |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | CORNELL UNIVERSITY (US) | 2023-12-05 | — | — | US | disclosed |
| WO-2023178107-A2 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023178107-A2 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK (US) | 2023-09-21 | — | — | WO | disclosed |
| US-7091373-B2 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-08-15 | — | — | US | disclosed |
| US-20040024229-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED | 2004-02-05 | — | — | US | disclosed |
| EP-1346971-A1 | Production method for biarylalanine | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040024229-A1 | Production method for biarylalanine | BCAT2, BCAT1, PAH | CTSS 1702/4885CTSK 2430/4885CACNA1B 2657/4885 |
| US-20260117274-A1 | ORTHOGONALLY CROSSLINKED PROTEINS, METHODS OF MAKING, AND USES THEREOF | PTMS, PSMG3, PSMB3 | CTSS 3065/4885CTSK 3616/4885CACNA1B 4746/4885 |
| US-11834515-B2 | Macrocyclic compounds as proteasome inhibitors | PSMB5, PSMB1, PSMB3 | CTSS 640/4885CTSK 1101/4885CACNA1B 4151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.